Anti-CD19 anti-CD 22 chimeric antigen receptor T cell therapy - Chongqing Precision Biotech
Alternative Names: Anti-CD19/Anti-CD22 CAR-T cell therapy-Chongqing Precision Biotech; CD19/CD22 dual CAR-T- Chongqing Precision BiotechLatest Information Update: 09 Mar 2021
At a glance
- Originator Chongqing Precision Biotech Co., Ltd
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II B-cell lymphoma; Leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 23 May 2021 Chongqing Precision Biotech initiates a phase I/II trial for B-cell lymphoma (In children, In adults, In adolescents, In the elderly, Second-line therapy or greater) in China (IV) (NCT04782193)
- 01 Jan 2021 Phase-I/II clinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma (In adolescents, In adults, In children, In the elderly, Second-line therapy or greater) in China (IV) (NCT04781634)
- 25 Aug 2020 Phase-I/II clinical trials in B-cell lymphoma (In children, In adults, In adolescents, In the elderly, Second-line therapy or greater) in China (IV) (NCT04648475)